What is claimed is:

1. Use of at least one compound chosen from (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile (rilzabrutinib) and pharmaceutically acceptable salts thereof in the manufacture of a medicament for treating itch associated with atopic dermatitis (AD) in a human patient in need thereof, wherein the medicament is to be administered to the human patient in a therapeutically effective amount for a treatment period.

2. Use of at least one compound chosen from (R)-2-[3-[4-amino-3-(2-fluoro-4-phenoxy-phenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine-1-carbonyl]-4-methyl-4-[4-(oxetan-3-yl)piperazin-1-yl]pent-2-enenitrile (rilzabrutinib) and pharmaceutically acceptable salts thereof in the manufacture of a medicament for treating itch associated with prurigo nodularis (PN) in a human patient in need thereof, wherein the medicament is to be administered to the human patient in a therapeutically effective amount for a treatment period.

3. The use of claim 1 or claim 2, wherein the human patient in need thereof has at least one of:
   (a) an inadequate response to topical corticosteroids (TCS);
   (b) an intolerance to TCS.

4. The use of any one of claims 1-3, wherein at least one of the following occurs:
   (a) the human patient has moderate-to-severe AD;
   (b) the human patient has moderate AD;
   (c) the human patient has severe AD.

5. The use of any one of claims 1-4, wherein the human patient has an inadequate response to topical corticosteroids (TCS).

6. The use of any one of claims 1-5, wherein the human patient has an intolerance to TCS.

7. The use of any one of claims 1-6, wherein the human patient has at least two, at least three, at least four, at least five, at least six, or all of the following characteristics:

(a) a history of atopic dermatitis (AD) for at least 12 months;

(b) an Eczema Area and Severity Index (EASI) score ≥12;

(c) an Investigator's Global Assessment (IGA) score ≥3 on the 0 to 4 IGA scale;

(d) a body surface area (BSA) of AD involvement score ≥10;

(e) an inadequate response or intolerance to topical corticosteroids (TCS) within 6 months prior to treatment;

(f) an inadequate response to one or more of cyclosporine, methotrexate, azathioprine, and mycophenolate;

(g) a baseline Peak Pruritis Numerical Rating Scale (PP-NRS) score for maximum itch intensity of ≥4.

8. The use of any one of claims 1-7, wherein at least one of the following occurs:

(a) the human patient achieves a Peak Pruritis Numerical Rating Scale (PP-NRS) score that is lower than baseline PP-NRS;

(b) the human patient achieves a PP-NRS score that is at least four points lower than baseline PP-NRS;

(c) the human patient achieves a PP-NRS score that is lower than baseline PP-NRS within three weeks of treatment;

(d) the human patient achieves a PP-NRS score that is at least four points lower than baseline PP-NRS within three weeks of treatment;

(e) the human patient achieves a PP-NRS score that is lower than baseline PP-NRS within two weeks of treatment;

(f) the human patient achieves a PP-NRS score that is lower than baseline PP-NRS within one week of treatment;

(g) the human patient achieves a PP-NRS score that is at least four points lower than baseline PP-NRS within one week of treatment.

9. The use of any one of claims 1-8, wherein:

(a) the human patient has baseline IgE levels of <300 Ul/mL; or

(b) the human patient has baseline IgE levels ≥300 Ul/mL.

10. The use of any one of claims 1-9, wherein the human patient is to be administered at least one concomitant treatment chosen from: low-to-medium potency TCS, topical crisaborole, and topical calcineurin inhibitors.

11. The use of any one of claims 1-10, wherein the treatment period is at least 16 weeks.

12. The use of any one of claims 1-11, wherein:

(a) the human patient is to be administered 400 mg of at least one compound chosen from rilzabrutinib and pharmaceutically acceptable salts thereof; or

(b) the human patient is to be administered 400 mg of at least one compound chosen from rilzabrutinib and pharmaceutically acceptable salts thereof, wherein:

(i) the at least one compound consists of at least one compound chosen from the (E) isomer of rilzabrutinib and pharmaceutically acceptable salts thereof;

(ii) the at least one compound consists of at least one compound chosen from the (Z) isomer of rilzabrutinib and pharmaceutically acceptable salts thereof; or

(iii) the at least one compound consists of a mixture of (E) and (Z) isomers of rilzabrutinib or a pharmaceutically acceptable salt of the foregoing.

13. The use of any one of claims 1-12, wherein

(a) the human patient is to be administered rilzabrutinib twice or thrice a day;

(b) the human patient is to be administered 400 mg of rilzabrutinib twice or thrice a day;

(c) the human patient is to be administer 400 mg of rilzabrutinib twice or thrice a day, wherein

(i) the at least one compound is the (E) isomer of rilzabrutinib;

(ii) the at least one compound is the (Z) isomer of rilzabrutinib;

(iii) the at least one compound consists of a mixture of (E) and (Z) isomers of rilzabrutinib;

(d) the human patient is to be administered 400 mg of rilzabrutinib twice a day;

(e) the human patient is to be administered 400 mg of rilzabrutinib thrice a day.

14. The use of any one of claims 1-13, wherein at least one of the following occurs:

(a) the human patient is to be administered the at least one compound orally;.

(b) the human patient is to be administered the at least one compound in the form of at least one tablet;

(c) the human patient is to be administered the at least one compound with water.

15. The use of any one of claims 1-5 and 7-14, wherein:

(a) the human patient is to be administered at least one topical corticosteroid (TCS);

(b) the human patient is to be administered at least one topical corticosteroid (TCS);

(i) the human patient is to be administered the TCS prior to administration of the at least one compound chosen from rilzabrutinib and pharmaceutically acceptable salts thereof;

(ii) the human patient is to be administered the TCS after administration of the at least one compound chosen from rilzabrutinib and pharmaceutically acceptable salts thereof;

(iii) the human patient is to be administered both the TCS and the at least one compound chosen from rilzabrutinib and pharmaceutically acceptable salts thereof on the same day or days.

16. The use of any one of claims 1-14, wherein the only therapeutic agent to be administered is the at least one compound chosen from rilzabrutinib and pharmaceutically acceptable salts thereof.

17. The use of any one of claims 1-16, wherein at least one of the following occurs:

(a) the human patient achieves a reduction in serum levels of TARC or IL-31.;

(b) the human patient achieves at least a 10% reduction, at least a 20% reduction, or at least a 30% reduction in serum levels of TARC;

(c) the human patient achieves a reduction in the expression of one or more of NGF-TrkA, TPH1, IL-31, NMBR, Alox5AP, and TPS1 in lesional skin.